Proteolix, Inc.
From Wikipedia, the free encyclopedia
 |
This article or section needs to be wikified to meet Wikipedia's quality standards. Please help improve this article with relevant internal links. (August 2007) |
 |
This article needs additional citations for verification. Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (August 2007) |
Proteolix, Inc., is a private biotechnology company with its headquarters in South San Francisco, California. Proteolix focuses primarily on the proteasome as a therapeutic target. Its lead product candidate, carfilzomib (PR-171), is a tetrapeptide epoxyketone currently in both Phase 1 and Phase 2 clinical trials in the United States and Canada. Carfilzomib's current route of administration is intravenous, and the company is exploring its potential utility in multiple myeloma, Non-Hodgkin lymphoma (NHL) and other cancers.
Proteolix's corporate website is [1].
This United States corporation or company article is a stub. You can help Wikipedia by expanding it.
